Smith Scott A, Sreenivasan R, Krishnasamy Gunasekaran, Judge Ken W, Murthy Krishna H, Arjunwadkar Shrihari J, Pugh David R, Kotwal Girish J
Division of Medical Virology, University of Cape Town Medical School, Anzio Road, Observatory, Cape Town, South Africa.
Biochim Biophys Acta. 2003 Aug 21;1650(1-2):30-9. doi: 10.1016/s1570-9639(03)00189-4.
The vaccinia virus complement control protein (VCP) is involved in modulating the host inflammatory response by blocking both pathways of complement activity through its ability to bind C3b and C4b. Other activities arise from VCP's ability to strongly bind heparin. To map regions within VCP involved in binding complement and heparin experimentally, surface plasmon resonance (SPR) and recombinantly expressed VCP (rVCP) constructs were employed. Using C3b or heparin as the immobilized ligand, various rVCP constructs were tested for their ability to bind. Results suggest that VCP is the smallest functional unit able to bind C3b, thereby blocking complement activity, and only a single site, the large basic region near the C-terminus, is involved in heparin binding. Kinetic analysis was also performed to determine the relative binding affinities between rVCP and complement (C3-MA and C4b), as well as rVCP and heparin. rVCP was found to possess a significantly greater affinity for C3-MA than C4b, as indicated by the 1.50e3-fold greater association rate constant (k(a)). This study provides insights for the design of new therapeutic proteins capable of blocking complement activation.
痘苗病毒补体控制蛋白(VCP)通过其结合C3b和C4b的能力阻断补体活性的两条途径,从而参与调节宿主炎症反应。VCP的其他活性源于其与肝素的强结合能力。为了通过实验确定VCP中参与结合补体和肝素的区域,采用了表面等离子体共振(SPR)和重组表达的VCP(rVCP)构建体。以C3b或肝素作为固定化配体,测试了各种rVCP构建体的结合能力。结果表明,VCP是能够结合C3b从而阻断补体活性的最小功能单元,并且只有一个位点,即靠近C端的大碱性区域,参与肝素结合。还进行了动力学分析,以确定rVCP与补体(C3-MA和C4b)以及rVCP与肝素之间的相对结合亲和力。如1.50e3倍更高的缔合速率常数(k(a))所示,发现rVCP对C3-MA的亲和力比对C4b的亲和力显著更高。这项研究为设计能够阻断补体激活的新型治疗性蛋白质提供了见解。